Ladenburg Thalmann Downgrades Optimer Pharmaceuticals (OPTR) to Neutral
OPTR Hot Sheet
Rating Summary:6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Ladenburg Thalmann downgrades Optimer Pharmaceuticals (Nasdaq: OPTR) from Buy to Neutral. Price target lowered from $17 to $13.50.
To see more analyst ratings on OPTR Click Here.
To see more analyst ratings on OPTR Click Here.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
- UBS Maintains a 'Neutral' on Patterson Companies (PDCO); Raising 'The Bar' and Estimates
Create E-mail Alert Related Categories
DowngradesRelated Entities
Ladenburg Thalmann Financial ServicesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
